Difficult to recognize clinically as they do not conform to the usually clinical findings.
Difficult to diagnose pathologically from benign Spitz tumors.
While 60-70% of melanomas have BRAF or N-RAS gene mutations leading to activation of the MARK pathway, such lesions have infrequent gene mutations, suggesting a distinct entity.